IGF1R and non-small cell lung carcinoma: For example, Han et al. demonstrated that downregulation of miR-223-3p promoted resistance of non-small cell lung cancer cells to erlotinib, an EGFR TKI, through activation of the IGF1R/PI3K/AKT pathway [43].